Cytokines and joint erosion in arthritis

Nature Clinical Practice Rheumatology

Volumn 4, Issue 2, 2008, Pages 58-59

  van den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DENOSUMAB; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY;

CARTILAGE DEGENERATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; HUMAN; JOINT DESTRUCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; REVIEW; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; INTERLEUKIN-17; JOINTS;

EID: 38949182314     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0683     Document Type: Review

References (10)

1. Smolen JS et al. (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52: 1020-1030
2. Zwerina J et al. (2007) TNF-induced structural damage is mediated by IL-1. Proc Natl Acad Sci USA 104: 11742-11747
3. Furst DE (2004) Anakinra: Review of recombinant human interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Clin Ther 26: 1960-1975
4. Miossec P (2007) Interleukin-17 in fashion, at last: Ten years after its description, its cellular source has been identified. Arthritis Rheum 56: 2111-2115
5. Koenders MI et al. (2006) Potential new targets in arthritis therapy: Interleukin (IL)-17 and its relation to tumor necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 65 (Suppl 3) iii29-iii33
6. Kirkham BW et al. (2006) Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: A two-year prospective study (the DAMAGE study cohort). Arthritis Rheum 54: 1122-1131
7. Scharstuhl A et al. (2003) Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors during experimental osteoarthritis. Arthritis Rheum 48: 3442-3451
8. Diarra D et al. (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13: 156-163
9. van Lent PL et al. (2006) Fogamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: Uncoupling of cartilage damage from bone erosion and joint inflammation. Arthritis Rheum 54: 3868-3877
10. Chopin F et al. (2007) Long term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis [doi:10.1136/ard.2007.076604]